Longeveron
Develops donor-derived cell therapy for pediatric cardiac and aging-related diseases.
Something off on this page? Send us feedback.
Profile
Develops laromestrocel, an investigational donor-derived cell therapy for pediatric cardiac and aging-related diseases, including HLHS and Alzheimer's disease. The clinical-stage business has no approved therapy sales, with all programs concentrated in the same candidate.
Develops laromestrocel (Lomecel-B), an investigational donor-derived mesenchymal stem-cell therapy, for hypoplastic left heart syndrome, mild Alzheimer's disease, pediatric dilated cardiomyopathy, and aging-related frailty. Its reported revenue comes from a Bahamas clinical-trial registry and third-party contract manufacturing rather than therapy sales.
Operates from Miami while running clinical activity across U.S. pediatric institutions. The lead HLHS program is being studied as an adjunct to staged surgery, while Alzheimer's and pediatric DCM development still depend on funding, partners, and trial execution. Every program depends on the same candidate, whose core cell-production technology is exclusively licensed from the University of Miami.
Company facts
Key statistics
Year to date +13.3% · Average volume (30d) 56.6K
Analysts
Ratings
Target range
Latest analyst notes
| Date | Firm | Action | Prior rating | Rating |
|---|---|---|---|---|
| May 11, 2026 | Maxim Group | Downgrade | Buy | Hold |
Earnings
EPS
Revenue
History
| Report date | EPS est | EPS | Surprise | Revenue est | Revenue | Surprise | Next session |
|---|---|---|---|---|---|---|---|
| Aug 12, 2026Q2 FY26 | −$0.18 | −$0.19 | −8.6% | $326.0K | $287.0K | −12.0% | −6.56% |
| May 13, 2026Q1 FY26 | −$0.19 | −$0.19 | 0.0% | $334.5K | $398.0K | +19.0% | −6.89% |
| Mar 17, 2026Q4 FY25 | −$0.42 | −$0.22 | +47.6% | $110.3K | $365.0K | +230.8% | +1.67% |
| Nov 4, 2025Q3 FY25 | −$0.26 | −$0.39 | −50.0% | $110.3K | $137.0K | +24.2% | −4.75% |
Financial highlights
| 12 quarters | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | |
|---|---|---|---|---|---|---|---|
| Revenue | $381.0K | $316.0K | $137.0K | $365.0K | $398.0K | $287.0K | |
| Gross profit | $275.0K | $146.0K | $125.0K | $257.0K | $264.0K | $182.0K | |
| Operating income | −$5.2M | −$5.4M | −$7.3M | −$5.4M | −$4.8M | −$6.2M | |
| Net income | −$5.0M | −$5.0M | −$7.2M | −$5.4M | −$4.7M | −$6.1M | |
| Diluted EPS | −$0.34 | −$0.33 | −$0.39 | −$0.24 | −$1.90 | −$1.90 | |
| Gross margin | 72.2% | 46.2% | 91.2% | 70.4% | 66.3% | 63.4% | |
| Operating margin | -1,359.8% | -1,707.9% | -5,335.8% | -1,479.2% | -1,199.7% | -2,150.2% |
Fiscal years (4-quarter sums)FY21 $1.3M · FY22 $1.2M · FY23 $668.0K · FY24 $2.4M · FY25 $1.2M
Balance sheet, Jun 30, 2026Cash & short-term investments $10.1M · Total debt $581.0K · Total assets $15.5M · Shareholders' equity $10.4M
Dividends
No dividends on record.
Ownership
Shares outstanding 3.04M · Float —
Float — provider float is below the insider stake.
The provider's float is smaller than the insider stake it should exclude, so it is not shown.
Insider tradesForm 4
No open-market trades in the last 12 months.
View detailsPeers
- Mesoblast (ADR)
Direct HLHS rival with a broad cardiac cell-therapy platform.
- Eli Lilly
Approved Kisunla shapes the early Alzheimer's treatment pathway.
- BioCardia
Cardiac cell-therapy rival in clinical development for heart failure.
CompareAfter-hours close
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Longeveron | $6.72 | 0.00% | $20.5M | — | — | 17.2 | −9.2% |
| Mesoblast (ADR) | $17.44 | −0.17% | $2.26B | — | — | 35.0 | +882.8% |
| Eli Lilly | $1,173.00 | −0.08% | $1.10T | 39.4 | 28.7 | 13.9 | +47.7% |
| BioCardia | $1.18 | +0.36% | $17.1M | — | — | — | — |
| Median | 39.4 | 28.7 | 24.4 | +465.2% |